Cargando…

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey

INTRODUCTION: This cross-sectional survey was conducted with National Psoriasis Foundation (NPF) to capture treatment perspectives and expectations in patients with psoriasis (PsO) using Patient Needs Questionnaire (PNQ) of Patient Benefit Index (PBI). METHODS: Adult participants with self-reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April, Edson-Heredia, Emily, Zhu, Baojin, Burge, Russel, Bell, Stacie, Crowley, Jeffery J., Smith, Stacy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122869/
https://www.ncbi.nlm.nih.gov/pubmed/35399114
http://dx.doi.org/10.1007/s12325-022-02124-2
_version_ 1784711437508149248
author Armstrong, April
Edson-Heredia, Emily
Zhu, Baojin
Burge, Russel
Bell, Stacie
Crowley, Jeffery J.
Smith, Stacy
author_facet Armstrong, April
Edson-Heredia, Emily
Zhu, Baojin
Burge, Russel
Bell, Stacie
Crowley, Jeffery J.
Smith, Stacy
author_sort Armstrong, April
collection PubMed
description INTRODUCTION: This cross-sectional survey was conducted with National Psoriasis Foundation (NPF) to capture treatment perspectives and expectations in patients with psoriasis (PsO) using Patient Needs Questionnaire (PNQ) of Patient Benefit Index (PBI). METHODS: Adult participants with self-reported diagnosis of PsO responded to the PNQ portion of PBI by indicating how much they valued different treatment attributes. All the treatment goals were captured on a five-point Likert scale (0 = “Not important”, 4 = “Very important”). Treatment goals were obtained for overall population and subgroups based on severity of disease Patient Global Assessment (PGA), age, gender, and Dermatology Life Quality Index (DLQI) total score. All data were expressed as mean and standard deviation [SD]. RESULTS: A total of 1200 participants completed the survey (mean age 51.5 years). Top treatment goal in the overall population was “to have confidence in the therapy” (3.46 [1.01]). Unique to the higher severity subgroup (PGA ≥ 3), “to find a clear diagnosis and therapy” was a top five goal and “to get better skin quickly” was for those with lesser severity (PGA < 3). “To be free of itching” (3.36 [0.99]) was the unique goal in the < 40 age group whereas it was “to get better skin quickly” (3.27 [1.12]) in the ≥ 40 group. In women and men, “to be free of itching” (3.38 [1.13]) and “to get better skin quickly” (3.20 [1.09]) were top five goals, respectively. Patients with ≥ 10 DLQI scores expressed higher treatment goal “to regain control of the disease” (3.66 [0.67]) compared to those with ≤ 10 DLQI scores who expressed “to have confidence in the therapy” (3.40 [1.11]) as the topmost treatment goal. CONCLUSION: Our results suggest that in patients with PsO, treatment preferences can vary with different characteristics such as age, severity, and gender as measured by using PNQ. Further exploration of this data will help inform treatment decisions and optimize patient outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02124-2.
format Online
Article
Text
id pubmed-9122869
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-91228692022-05-22 Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey Armstrong, April Edson-Heredia, Emily Zhu, Baojin Burge, Russel Bell, Stacie Crowley, Jeffery J. Smith, Stacy Adv Ther Original Research INTRODUCTION: This cross-sectional survey was conducted with National Psoriasis Foundation (NPF) to capture treatment perspectives and expectations in patients with psoriasis (PsO) using Patient Needs Questionnaire (PNQ) of Patient Benefit Index (PBI). METHODS: Adult participants with self-reported diagnosis of PsO responded to the PNQ portion of PBI by indicating how much they valued different treatment attributes. All the treatment goals were captured on a five-point Likert scale (0 = “Not important”, 4 = “Very important”). Treatment goals were obtained for overall population and subgroups based on severity of disease Patient Global Assessment (PGA), age, gender, and Dermatology Life Quality Index (DLQI) total score. All data were expressed as mean and standard deviation [SD]. RESULTS: A total of 1200 participants completed the survey (mean age 51.5 years). Top treatment goal in the overall population was “to have confidence in the therapy” (3.46 [1.01]). Unique to the higher severity subgroup (PGA ≥ 3), “to find a clear diagnosis and therapy” was a top five goal and “to get better skin quickly” was for those with lesser severity (PGA < 3). “To be free of itching” (3.36 [0.99]) was the unique goal in the < 40 age group whereas it was “to get better skin quickly” (3.27 [1.12]) in the ≥ 40 group. In women and men, “to be free of itching” (3.38 [1.13]) and “to get better skin quickly” (3.20 [1.09]) were top five goals, respectively. Patients with ≥ 10 DLQI scores expressed higher treatment goal “to regain control of the disease” (3.66 [0.67]) compared to those with ≤ 10 DLQI scores who expressed “to have confidence in the therapy” (3.40 [1.11]) as the topmost treatment goal. CONCLUSION: Our results suggest that in patients with PsO, treatment preferences can vary with different characteristics such as age, severity, and gender as measured by using PNQ. Further exploration of this data will help inform treatment decisions and optimize patient outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02124-2. Springer Healthcare 2022-04-11 2022 /pmc/articles/PMC9122869/ /pubmed/35399114 http://dx.doi.org/10.1007/s12325-022-02124-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Armstrong, April
Edson-Heredia, Emily
Zhu, Baojin
Burge, Russel
Bell, Stacie
Crowley, Jeffery J.
Smith, Stacy
Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title_full Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title_fullStr Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title_full_unstemmed Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title_short Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
title_sort treatment goals for psoriasis as measured by patient benefit index: results of a national psoriasis foundation survey
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122869/
https://www.ncbi.nlm.nih.gov/pubmed/35399114
http://dx.doi.org/10.1007/s12325-022-02124-2
work_keys_str_mv AT armstrongapril treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT edsonherediaemily treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT zhubaojin treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT burgerussel treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT bellstacie treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT crowleyjefferyj treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey
AT smithstacy treatmentgoalsforpsoriasisasmeasuredbypatientbenefitindexresultsofanationalpsoriasisfoundationsurvey